Kevin Tang, Director at Heron Therapeutics, holds 372.00K shares in Singular Genomics Systems (Ticker: OMIC), holds 3.85M shares in Rain Oncology (Ticker: RAIN), holds 4.39M shares in TCR2 Therapeutics (Ticker: TCRR). Most recently, Kevin Tang Bought ― shares of Singular Genomics Systems on Sep 18, 2024 for an estimated value of 1.81M.
Kevin Tang latest transaction was an Informative Buy of $1.81M.
What was Kevin Tang's most profitable transaction?
Kevin Tang’s most profitable transaction was an Informative Buy of LJPC stock on September 26, 2014. The return on the trade was 228.40%.
What is Kevin Tang's role in Heron Therapeutics?
Kevin Tang's role in Heron Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.